FDA draft biosimilar guidance removes animal toxicology and immunogenicity requirements
FDA draft biosimilar guidance released March 10, 2026 removes animal toxicology and immunogenicity requirements and accepts some non-U.S. comparator data. The changes are projected to cut development costs by up to 50%.
The U.S. Food and Drug Administration on March 10, 2026 released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4). The guidance eliminates tiered analytical similarity assessments, removes animal toxicology requirements as standard studies, and reflects an updated framework that removes comparative immunogenicity studies for highly similar biologic products.
The new guidance also accepts data from non-U.S. comparator studies when scientifically justified, eliminating the need for duplicative pharmacokinetic studies. Updated interchangeability guidance issued in 2024 reflects alternatives to full interchangeability designation, and the new draft codifies an IND framework tailored to biosimilar programs and greater reliance on modern analytical characterization rather than clinical confirmation.
The guidance is projected to reduce biosimilar development costs by as much as 50 percent, roughly $20 million per program, opening a market long dominated by large pharmaceutical firms to smaller biotechnology companies. Biosimilar development has historically cost $100–$200 million per product, limiting participation to large multinational firms.
Biologics constitute approximately 5% of U.S. prescriptions yet roughly 51% of total drug spending. The global biosimilars market reached approximately $30 billion in 2024 and could generate over $180 billion in U.S. healthcare savings in coming years.
Two unresolved issues remain: USP standardized biologic release specifications and patent doping. A pending petition would authorize the United States Pharmacopeia to develop standardized product specifications for biologics, which would eliminate the need for expensive reference-product comparisons in every biosimilar program. The article also said originator manufacturers file cascades of secondary patents to delay biosimilar entry even after primary patent expiration, while Congress and the USPTO have yet to act on corrective measures.